AOL Money & Finance

Eli Lilly posts quarterly earnings

More

Earlier today, pharmaceutical firm Eli Lilly (NYSE: LLY) announced that it suffered a fourth-quarter loss thanks to charges suffered when purchasing ImClone Systems. Excluding these charges, LLY tallied $1.07 per share in the quarter -- topping analysts' estimates for $1.05 per share. Taking the ImClone acquisition (which cost LLY $4.73 billion in charges) into account, LLY lost $3.31 per share during the quarter. Quarterly revenue checked in at $5.42 billion.

LLY saw flat sales for the quarter, along with a 10% drop in Zyprexa - its top-selling drug. The anti-psychotic medication saw sales slip $1.15 billion, which was attributed to decreased wholesale buying in the U.S. and lower foreign sales thanks to lower prices and less-favorable exchange rates. On a full-year basis, Zyprexa sales fell 1% to $4.7 billion. Zyprexa sales totaled 22% of LLY's yearly sales, down 3% from a year earlier. Cymbalta, LLY's second-best selling drug, cushioned the Zyprexa news a bit, as it saw sales increase by 15%. Eight of LLY's drugs raked in more than $1 billion in sales, better than the six that notched those sales a year earlier.

For the full year, LLY lost $2.07 billion. Excluding items, the pharmaceutical firm's adjusted profit came in at $4.02 per share, up from $3.54 per share a year earlier. Full-year revenue increased 9% to $20.38 billion.

The firm also affirmed its profit forecast of $4 to $4.25 per share, which surrounds the Street's expected results of $4.19 per share. LLY shares have dropped slightly more than a percent today. The stock has performed well lately, but it has encountered a bit of resistance in the $40 region.

Reader Comments (Page 1 of 1)

Symbol Lookup
IndexesChangePrice
DJIA-9.2210,441.73
NASDAQ-6.672,169.34
S&P 500-0.211,106.03

Last updated: November 24, 2009: 03:33 PM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

TheFlyOnTheWall.com Headlines

BioHealth Investor Headlines

WalletPop Headlines

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

WalletPop Headlines